Anti-angiogenic drug discovery: lessons from the past and thoughts for the future

Clinical outcomes in bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP).

(2017) A. L. Cohn et al.   JOURNAL OF CLINICAL ONCOLOGY

Hypertension (HTN) and proteinuria (PTN) as biomarkers of efficacy in antiangiogenic therapy for metastatic colorectal cancer (mCRC).

(2017) Y. K. Zee et al.   JOURNAL OF CLINICAL ONCOLOGY

High-dose bevacizumab in the treatment of patients with advanced clear cell renal carcinoma (RCC): A Sarah Cannon Research Institute phase II trial.

(2017) A. A. Meluch et al.   JOURNAL OF CLINICAL ONCOLOGY

Using bevacizumab to treat metastatic cancer: UK consensus guidelines

(2014) D Miles et al.   BRITISH JOURNAL OF HOSPITAL MEDICINE

Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma

(2012) Sergio Vázquez et al.   ADVANCES IN THERAPY

Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs

(2012) Astrid A.M. Van der Veldt et al.   CANCER CELL

Vascular Normalization by Loss of Siah2 Results in Increased Chemotherapeutic Efficacy

(2012) C. S. F. Wong et al.   CANCER RESEARCH

Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy

(2012) Laura Horsley et al.   Expert Opinion on Drug Metabolism & Toxicology

Targeted therapy of hepatocellular carcinoma: Present and future

(2012) Stephen L Chan et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Tumor Cell Plasticity and Angiogenesis in Human Melanomas

(2012) Daniela Mihic-Probst et al.   PLoS One

Effect of Angiogenesis Inhibitor Bevacizumab on Survival in Patients with Cancer: A Meta-Analysis of the Published Literature

(2012) Yuan Su et al.   PLoS One

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

(2011) C. Bokemeyer et al.   ANNALS OF ONCOLOGY

A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer

(2011) M. Reck et al.   ANNALS OF ONCOLOGY

Signal transduction by vascular endothelial growth factor receptors

(2011) Sina Koch et al.   BIOCHEMICAL JOURNAL

The angiogenic process as a therapeutic target in cancer

(2011) Esther M. Bridges et al.   BIOCHEMICAL PHARMACOLOGY

Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib

(2011) F Di Fiore et al.   BRITISH JOURNAL OF CANCER

Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of "Rebound" Revascularization as Mode of Escape

(2011) E. di Tomaso et al.   CANCER RESEARCH

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Matrix metalloproteinases in tumorigenesis: an evolving paradigm

(2011) Hui Hua et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer

(2011) A. M. Jubb et al.   CLINICAL CANCER RESEARCH

Appropriate end-points for right results in the age of antiangiogenic agents: Future options for phase II trials in patients with recurrent glioblastoma

(2011) A.A. Brandes et al.   EUROPEAN JOURNAL OF CANCER

Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials

(2011) Xiao Feng Hang et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Clinical end points in recurrent glioblastoma: are antiangiogenic agents friend or foe?

(2011) Enrico Franceschi et al.   Expert Review of Anticancer Therapy

Emerging paradigms and questions on pro-angiogenic bone marrow-derived myelomonocytic cells

(2011) Julien Laurent et al.   INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

(2011) Nicholas J. Robert et al.   JOURNAL OF CLINICAL ONCOLOGY

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

(2011) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical significance of vasculogenic mimicry in human gliomas

(2011) Xiao-mei Liu et al.   JOURNAL OF NEURO-ONCOLOGY

Advanced or metastatic gastrointestinal stromal tumors: Systemic treatment options

(2011) Megan V. Caram et al.   JOURNAL OF SURGICAL ONCOLOGY

Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

(2011) B. I. Rini et al.   JNCI-Journal of the National Cancer Institute

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or with Endostar for Advanced Non-small Cell Lung Cancer

(2011) Baohui Han et al.   Journal of Thoracic Oncology

Vascular endothelial growth factors and receptors: Anti-angiogenic therapy in the treatment of cancer

(2011) Sònia Tugues et al.   MOLECULAR ASPECTS OF MEDICINE

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

(2011) F. M. Yakes et al.   MOLECULAR CANCER THERAPEUTICS

Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: One step forward for overcoming anti-angiogenic drug resistance?

(2011) Iris Helfrich et al.   Molecular Oncology

Tumor angiogenesis: molecular pathways and therapeutic targets

(2011) Sara M Weis et al.   NATURE MEDICINE

Antiangiogenic therapy: impact on invasion, disease progression and metastasis

(2011) John M. L. Ebos et al.   Nature Reviews Clinical Oncology

Clinical trial end points for high-grade glioma: the evolving landscape

(2011) D. A. Reardon et al.   NEURO-ONCOLOGY

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

(2011) Eric Raymond et al.   NEW ENGLAND JOURNAL OF MEDICINE

Identification and angiogenic role of the novel tumor endothelial marker CLEC14A

(2011) M Mura et al.   ONCOGENE

Normalization of the Vasculature for Treatment of Cancer and Other Diseases

(2011) Shom Goel et al.   PHYSIOLOGICAL REVIEWS

Functional and Structural Characteristics of Tumor Angiogenesis in Lung Cancers Overexpressing Different VEGF Isoforms Assessed by DCE- and SSCE-MRI

(2011) Ang Yuan et al.   PLoS One

Transdifferentiation of glioblastoma cells into vascular endothelial cells

(2011) Y. Soda et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment

(2011) R. C. S. Seet et al.   QJM-AN INTERNATIONAL JOURNAL OF MEDICINE

Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study

(2011) Vaneja Velenik et al.   Radiation Oncology

Economic burden of toxicities associated with metastatic colorectal cancer treatment regimens containing monoclonal antibodies

(2011) Chakkarin Burudpakdee et al.   JOURNAL OF MEDICAL ECONOMICS

Tumor Angiogenesis: Pericytes and Maturation Are Not to Be Ignored

(2011) Elham Fakhrejahani et al.   Journal of Oncology

VEGF-PET Imaging Is a Noninvasive Biomarker Showing Differential Changes in the Tumor during Sunitinib Treatment

(2010) W. B. Nagengast et al.   CANCER RESEARCH

Experience with sorafenib and adverse event management

(2010) Joaquim Bellmunt et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Phase II study of Cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium

(2010) Ajjai Alva et al.   INVESTIGATIONAL NEW DRUGS

Phase II Proof-of-Concept Study of Pazopanib Monotherapy in Treatment-Naive Patients With Stage I/II Resectable Non–Small-Cell Lung Cancer

(2010) Nasser Altorki et al.   JOURNAL OF CLINICAL ONCOLOGY

Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

(2010) Hedy Lee Kindler et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

(2010) David W. Miles et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival

(2010) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

(2010) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials

(2010) David Miles et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08

(2010) Carmen J. Allegra et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Imaging of Changes in the Prevalence of Vascular Endothelial Growth Factor Receptor in Sunitinib-Treated Murine Mammary Tumors

(2010) Z. Levashova et al.   JOURNAL OF NUCLEAR MEDICINE

Angiogenesis and Current Antiangiogenic Strategies for the Treatment of Cancer

(2010) Rahmi Oklu et al.   JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

(2010) Federico Cappuzzo et al.   LANCET ONCOLOGY

Finding the tumor copycat: Approximating a human cancer

(2010) Terry Van Dyke   NATURE MEDICINE

Finding the tumor copycat: Therapy fails, patients don't

(2010) Lee M Ellis et al.   NATURE MEDICINE

Increased Risk of Serious Hemorrhage with Bevacizumab in Cancer Patients: A Meta-Analysis

(2010) Sanjaykumar Hapani et al.   ONCOLOGY

Flare-up: An often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors

(2009) Pascal Wolter et al.   ACTA ONCOLOGICA

Renal Effects of Anti-angiogenesis Therapy: Update for the Internist

(2009) Faina Gurevich et al.   AMERICAN JOURNAL OF MEDICINE

A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients

(2009) A. Gregory Sorensen et al.   CANCER RESEARCH

Phase I/II Trial of Bevacizumab and Radiotherapy for Locally Advanced Inoperable Colorectal Cancer: Vasculature-Independent Radiosensitizing Effect of Bevacizumab

(2009) M. I. Koukourakis et al.   CLINICAL CANCER RESEARCH

Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis

(2009) Cristina Rodríguez-Antona et al.   ENDOCRINE-RELATED CANCER

Current status and future prospects for anti-angiogenic therapies in cancer

(2009) Carolyn A Staton et al.   Expert Opinion on Drug Discovery

Imaging glioma cell invasionin vivoreveals mechanisms of dissemination and peritumoral angiogenesis

(2009) Frank Winkler et al.   GLIA

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

(2009) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Issues in Using Progression-Free Survival When Evaluating Oncology Products

(2009) Thomas R. Fleming et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study

(2009) Christopher G. Willett et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

(2009) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis

(2009) Sanjaykumar Hapani et al.   LANCET ONCOLOGY

Real-time imaging reveals the single steps of brain metastasis formation

(2009) Yvonne Kienast et al.   NATURE MEDICINE

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer

(2009) Jolien Tol et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-Epidermal Growth Factor Receptor Monotherapy in the Treatment of Metastatic Colorectal Cancer: Where Are We Today?

(2009) M. Peeters et al.   ONCOLOGIST

Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

(2009) K. P. Olive et al.   SCIENCE

Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance

(2009) Yihai Cao et al.   SEMINARS IN CANCER BIOLOGY

Slits and Roundabouts in cancer, tumour angiogenesis and endothelial cell migration

(2008) John A. Legg et al.   ANGIOGENESIS

Angiogenesis in pre-malignant conditions

(2008) S R Menakuru et al.   BRITISH JOURNAL OF CANCER

Reversible posterior leukoencephalopathy syndrome associated with bevacizumab/doxorubicin regimen

(2008) Franck Bürki et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacology of the Novel Antiangiogenic Peptide ATN-161 (Ac-PHSCN-NH2): Observation of a U-Shaped Dose-Response Curve in Several Preclinical Models of Angiogenesis and Tumor Growth

(2008) F. Donate et al.   CLINICAL CANCER RESEARCH

Sunitinib Reverses Type-1 Immune Suppression and Decreases T-Regulatory Cells in Renal Cell Carcinoma Patients

(2008) J. H. Finke et al.   CLINICAL CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Feasibility of Using Bevacizumab With Radiation Therapy and Temozolomide in Newly Diagnosed High-Grade Glioma

(2008) Ashwatha Narayana et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients

(2008) Shobha Rani Nalluri et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Recurrent Priapism Related to Oxaliplatin Infusion

(2008) Antoine Adenis et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

(2008) Leonard B. Saltz et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)

(2008) Axel Grothey et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme

(2008) David A. Reardon et al.   JOURNAL OF CLINICAL ONCOLOGY

Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer

(2008) Silvia Dellapasqua et al.   JOURNAL OF CLINICAL ONCOLOGY

Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group

(2008) Howard I. Scher et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Overexpression of VEGF is associated with positive p53 immunostaining in hepatocellular carcinoma (HCC) and adverse outcome of HCC patients

(2008) Po-Lin Tseng et al.   JOURNAL OF SURGICAL ONCOLOGY

Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation

(2008) W Zhao et al.   LEUKEMIA

Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas

(2008) Kathleen R. Lamborn et al.   NEURO-ONCOLOGY

Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence

(2008) A. D. Norden et al.   NEUROLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor Angiogenesis

(2008) Robert S. Kerbel   NEW ENGLAND JOURNAL OF MEDICINE

Endpoints for Assessing Drug Activity in Clinical Trials

(2008) R. Pazdur   ONCOLOGIST

Crystal structure of CD155 and electron microscopic studies of its complexes with polioviruses

(2008) P. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?

(2008) Cristiana Sessa et al.   Nature clinical practice. Oncology

Development trends for new cancer therapeutics and vaccines

(2007) J REICHERT   DRUG DISCOVERY TODAY